Clinical outcomes after CD28-costimulated CART19 according to the LD regimen administered. (A) Three-month response according to LD regimen administered after axi-cel infusion in the entire cohort. (B) PFS according to LD regimen in the entire cohort. (C) OS according to LD administered in the entire cohort. (D) Three-month response according to LD regimen administered after axi-cel infusion in the LBCL cohort. (E) PFS according to LD regimen in the LBCL cohort. (F) OS according to LD administered in the LBCL cohort. (G) Three-month response according to LD regimen administered after axi-cel infusion in the FL cohort. (H) PFS according to LD regimen in the FL cohort. (I) OS according to LD administered in the FL cohort. Red lines represent patients treated with Flu/Cy, whereas the blue lines represent patients treated with Benda. CI, confidence interval; CR, complete response; NR, no response; PR, partial response; PFS, progression-free survival; OS, overall survival.